Ke Qiao, Wang Lei, Lin Ziguo, Lou Jianying, Zheng Shuguo, Bi Xinyu, Wang Jianming, Guo Wei, Li Fuyu, Wang Jian, Zheng Yamin, Li Jingdong, Cheng Shi, Zhou Weiping, Zeng Yongyi
Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Department of Radiation Oncology, Fujian Cancer Hospital, The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Front Oncol. 2021 Mar 11;11:585808. doi: 10.3389/fonc.2021.585808. eCollection 2021.
The clinical value of lymph-node dissection (LND) for intrahepatic carcinoma (ICC) patients with clinically negative lymph node metastasis (LNM) remains unclear; hence we conducted a multi-center study to explore it.
Patients who were diagnosed ICC with clinically negative LNM and underwent hepatectomy with or without LND from December 2012 to December 2015 were retrospectively collected from 12 hepatobiliary centers in China. Overall survival (OS) was analyzed using the Kaplan-Meier method, and then subgroup analysis was conducted stratified by variables related to the prognosis.
A total of 380 patients were eligible including 106 (27.9%) in the LND group and 274 (72.1%) in the non-LND group. Median OS in the LND group was slightly longer than that in the non-LND group (24.0 18.0 months, = 0.30), but a significant difference was observed between the two groups (24.0 14.0 months, = 0.02) after a well-designed 1:1 propensity score matching without increased severe complications. And, LND was identified to be one of the independent risk factors of OS (HR = 0.66, 95%CI = 0.46-0.95, = 0.025). Subgroup analysis in the matched cohort showed that patients could benefit more from LND if they were male, age <60 years, had no HBV infection, with ECOG score <2, CEA ≤5 ug/L, blood loss ≤400 ml, transfusion, major hepatectomy, resection margin ≥1 cm, tumor size >5 cm, single tumor, mass-forming, no satellite, no MVI, and no perineural invasion (all < 0.05). Furthermore, only patients with pathologically confirmed positive LNM were found to benefit from postoperative adjuvant therapy ( < 0.001).
With the current data, we concluded that LND would benefit the selected ICC patients with clinically negative LNM and might guide the postoperative management.
对于临床淋巴结转移(LNM)阴性的肝内胆管癌(ICC)患者,淋巴结清扫术(LND)的临床价值仍不明确;因此,我们开展了一项多中心研究来进行探索。
回顾性收集2012年12月至2015年12月期间在中国12个肝胆中心诊断为ICC且临床LNM阴性并接受了肝切除术(无论是否进行LND)的患者。采用Kaplan-Meier法分析总生存期(OS),然后根据与预后相关的变量进行分层亚组分析。
共有380例患者符合条件,其中LND组106例(27.9%),非LND组274例(72.1%)。LND组的中位OS略长于非LND组(24.0对18.0个月,P = 0.30),但在经过精心设计的1:1倾向评分匹配后,两组之间观察到显著差异(24.0对14.0个月,P = 0.02),且未增加严重并发症。并且,LND被确定为OS的独立危险因素之一(HR = 0.66,95%CI = 0.46 - 0.95,P = 0.025)。匹配队列中的亚组分析表明,如果患者为男性、年龄<60岁、无HBV感染、ECOG评分<2、CEA≤5μg/L、失血量≤400ml、输血、大肝切除术、切缘≥1cm、肿瘤大小>5cm、单发病灶、肿块型、无卫星灶、无微血管侵犯(MVI)且无神经周围侵犯,则他们可能从LND中获益更多(均P<0.05)。此外,仅病理证实LNM阳性的患者被发现从术后辅助治疗中获益(P<0.001)。
基于目前的数据,我们得出结论,LND将使选定的临床LNM阴性的ICC患者获益,并可能指导术后管理。